Arvinas

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Arvinas and other ETFs, options, and stocks.

About ARVN

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. 

CEO
John G. Houston
CEOJohn G. Houston
Employees
445
Employees445
Headquarters
New Haven, Connecticut
HeadquartersNew Haven, Connecticut
Founded
2013
Founded2013
Employees
445
Employees445

ARVN Key Statistics

Market cap
2.83B
Market cap2.83B
Price-Earnings ratio
-6.36
Price-Earnings ratio-6.36
Dividend yield
Dividend yield
Average volume
900.21K
Average volume900.21K
High today
$41.98
High today$41.98
Low today
$40.84
Low today$40.84
Open price
$41.71
Open price$41.71
Volume
490.55K
Volume490.55K
52 Week high
$53.08
52 Week high$53.08
52 Week low
$13.57
52 Week low$13.57

Analyst ratings

89%

of 19 ratings
Buy
89.5%
Hold
10.5%
Sell
0%
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.